Recent Updates
Recently added Catalysts
CHRS

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

Key Takeaway: REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4th, 2022. Starting at 5 p.m. ET, Coherus’ managemen
Price reaction · baseline $8.09 (2022-07-27 close) · hit after-hours · 1 other CHRS headline(s) in the window, move may be shared
day 0 close · peak
+4.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+136%
120-day peak, hindsight
Typical move
6.6%
average across 12 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
CHS-0214
Phase 3 · Rheumatoid Arthritis

Full Press Release Details

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4th, 2022. Starting at 5 p.m. ET, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
After releasing second quarter 2022 financial results, the Company will post them on the Coherus website at https://investors.coherus.com.
Conference Call Information
When: Thursday, August 4th, 2022, starting at 5 p.m. ET
Dial-in: (800) 715-9871 (Toll-Free U.S. and Canada) or (646) 307-1963 (International)
Conference ID: 8699439
Please dial-in 15 minutes early to ensure a timely connection to the call.
Coherus Contact Information:
Marek Ciszewski, J.D.
SVP, Investor Relations
Coherus BioSciences, Inc.
Last updated: Jul 28, 2022